| Accession Number: | 0001437749-21-008332 |
| Date: | 2021-04-01 |
| Issuer: | BIOLIFE SOLUTIONS INC (BLFS) |
| Original Submission Date: |
FOSTER KAREN A.
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL, WA 98021
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2021-04-01 | M | 8,797 | a | $0.00 | 74,208 | direct | ||
| COMMON STOCK | 2021-04-01 | S | 3,414 | d | $36.53 | 70,794 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | the reporting person was granted restricted stock pursuant to the biolife solutions 2013 performance incentive plan (as amended, the "plan") on march 25, 2020. in accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. the grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. |
| f2 | the sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
